Research Papers:

Low expression of CD200 predicts shorter time-to-treatment in chronic lymphocytic leukemia

Yi Miao, Lei Fan _, Yu-Jie Wu, Yi Xia, Chun Qiao, Yan Wang, Li Wang, Min Hong, Hua-Yuan Zhu, Wei Xu and Jian-Yong Li

PDF  |  HTML  |  How to cite

Oncotarget. 2016; 7:13551-13562. https://doi.org/10.18632/oncotarget.6948

Metrics: PDF 2356 views  |   HTML 2313 views  |   ?  


Yi Miao1, Lei Fan1, Yu-Jie Wu1, Yi Xia1, Chun Qiao1, Yan Wang1, Li Wang1, Min Hong1, Hua-Yuan Zhu1, Wei Xu1, Jian-Yong Li1,2

1Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing 210029, China

2Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing Medical University, Nanjing 210029, China

Correspondence to:

Lei Fan, e-mail: [email protected]

Wei Xu, e-mail: [email protected]

Jian-Yong Li, e-mail: [email protected]

Keywords: CD200, mean fluorescence intensity, chronic lymphocytic leukemia, prognosis, time to treatment

Received: May 01, 2015     Accepted: December 26, 2015     Published: January 19, 2016


CD200, formerly known as OX-2, is a type I glycoprotein that is expressed on a variety of cell types. CD200 has been shown to be overexpressed in chronic lymphocytic leukemia (CLL). Although previous studies have confirmed the diagnostic value of CD200 in differentiating CLL from to other B-cell chronic lymphoproliferative disorders especially mantle cell lymphoma, whether CD200 has prognostic significance in CLL remains to be determined. We evaluated the mean fluorescence intensity (MFI) of CD200 in 307 consecutive, untreated patients with CLL in our center using flow cytometry. Using a CD200 MFI cutoff of 189.5, these cases could be divided into two groups. Patients with lower CD200 MFI (< 189.5) had a significantly shorter time-to-treatment (TTT) than those with higher CD200 MFI (≥ 189.5) (median TTT: 2 months vs 28 months, p = 0.0008). However, the effect of CD200 MFI on overall survival was not significant (CD200 MFI < 189.5: undefined vs CD200 MFI ≥ 189.5: undefined, P = 0.2379). In subgroup analysis, CD200 MFI retained its prognostic value in patients with favourable characteristics such as Binet stage A disease, mutated IGHV status, normal TP53 or negative CD38 expression. In conclusion, our study identified CD200 MFI as a potential prognostic factor in CLL.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 6948